Future vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Future pairs members with 130+ expert human coaches at $199/month using Apple Watch biometrics; 4.9-star rated app with $108M raised ($75M Series C). Founded 2017, San Francisco.
About
Future was founded in 2017 in San Francisco with the mission of making expert personal training accessible to anyone, not just athletes or the wealthy who can afford in-person coaching. The company built a digital personal training platform that pairs each member with a dedicated human coach who designs individualized workout plans, monitors progress through Apple Watch biometric data, and provides real-time feedback through the app. Future's core philosophy is that accountability and personalization — not generic content — are what actually drive sustained behavior change and fitness results.\n\nFuture's platform pairs members with more than 130 expert coaches who have backgrounds in strength and conditioning, sports performance, and clinical exercise science. Coaches review member activity daily, adjust programming based on recovery and performance data, and communicate directly through the app — creating a relationship-driven coaching model at digital scale. The service is priced at $199 per month, positioning it as a premium alternative to both in-person personal training and algorithm-driven fitness apps. Future integrates deeply with Apple Watch to capture heart rate, workout metrics, and activity data, giving coaches objective performance signals to inform programming decisions.\n\nFuture has raised $108 million in total, including a $75 million Series C, and maintains a 4.9-star rating in the App Store across tens of thousands of reviews — a remarkable signal of member satisfaction in a category often plagued by high churn. The company's human-plus-AI coaching model occupies a distinct position between the low-cost digital fitness market and the high-cost in-person coaching market, and its 130-plus coach network gives it a proprietary talent asset that is difficult to replicate. As demand for personalized health and longevity programs grows among high-income professionals, Future's model scales coach capacity through AI-assisted tools while preserving the relational quality that drives retention.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.